Repository hosted by TU Delft Library

Home · Contact · About · Disclaimer ·
 

Effects of non-oral postmenopausal hormone therapy on markers of cardiovascular risk: a systematic review

Publication files not online:

Author: Hemelaar, M. · Mooren, M.J. van der · Rad, M. · Kluft, C. · Kenemans, P.
Type:article
Date:2008
Institution: TNO Kwaliteit van Leven
Source:Fertility and Sterility, 3, 90, 642-672
Identifier: 240981
doi: doi:10.1016/j.fertnstert.2007.07.1298
Keywords: Biology · cardiovascular disease · intranasal · Postmenopausal hormone therapy · risk factors · transdermal · venous thromboembolism · activated protein C · antithrombin · blood clotting factor 7 · C reactive protein · cell adhesion molecule · chlormadinone acetate · conjugated estrogen · cyproterone acetate plus estradiol valerate · dydrogesterone · dydrogesterone plus estradiol · endothelin 1 · estradiol · estradiol valerate · estrone sulfate · gestodene · homocysteine · hormone · lipoprotein · medrogestone · medroxyprogesterone acetate · n(g),n(g) dimethylarginine · nomegestrol acetate · norethisterone acetate · placebo · progesterone · protein C · protein S · prothrombin · article · atherosclerosis · blood clotting · cardiovascular risk · clinical trial · drug effect · drug mechanism · endothelial dysfunction · fibrinolysis · follow up · hormonal therapy · human · inflammation · ischemic heart disease · outcome assessment · postmenopause · priority journal · systematic review · venous thromboembolism · Administration, Oral · Atherosclerosis · Biological Markers · Estrogen Replacement Therapy · Estrogens · Female · Humans · Incidence · Risk Assessment · Risk Factors · Venous Thrombosis

Abstract

Objective: To review the effects of non-oral administration of postmenopausal hormone therapy (HT) on risk markers for atherosclerotic and venous thromboembolic disease.Non-oral postmenopausal HT appears not to increase venous thromboembolic risk, whereas the effect on coronary heart disease risk is less clear. Design: Systematic review of literature obtained from MEDLINE, EMBASE, and CENTRAL databases from 1980 until and including April 2006. Terms for "postmenopausal hormone therapy" and for "non-oral administration" were combined in the search. Setting: Randomized clinical trials. Patient(s): Postmenopausal women, both healthy and with established cardiovascular disease or specified cardiovascular risk factors. Intervention(s): Non-oral HT (e.g., transdermal or intranasal) compared with oral HT or no treatment/placebo. Main Outcome Measure(s): Lipoprotein(a), homocysteine, C-reactive protein (CRP), cell adhesion molecules, markers of endothelial dysfunction, coagulation, and fibrinolysis. Result(s): Seventy-two studies investigating either transdermal or intranasal administration were included. For non-oral HT, decreases in lipoprotein(a), cell adhesion molecules, and factor VII generally were significant, resistance to activated protein C (APCr) was slightly increased, and other markers including CRP and homocysteine did not change. Compared with oral HT, changes in CRP and APCr were smaller, changes in cell adhesion molecules and some fibrinolytic parameters tended to be smaller, whereas changes in other factors including lipoprotein(a) and homocysteine did not differ. Conclusion(s): Potentially unfavorable changes seen with oral HT on two important markers, CRP and APCr, are substantially smaller with non-oral HT. Non-oral HT has minor effects on the other cardiovascular risk markers studied. Therefore, compared with oral HT, non-oral HT appears be safer with respect to atherosclerotic and venous thromboembolic disease risk. © 2008 American Society for Reproductive Medicine.